Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5+ Diffuse Large B-Cell Lymphoma

Objective: To investigate the clinical characteristics and treatment of relapsed CD5+ diffuse large B-cell lymphoma (DLBCL).

Methods: The data of a patient with CD5+ DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.

Results: The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.

Conclusions: PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5+ DLBCL.